Prosecution Insights
Last updated: November 04, 2026
Application No. 17/341,027

PREVENTING OR MITIGATING CHEMOTHERAPY INDUCED ALOPECIA USING VITAMIN D

Non-Final OA §103§DP
Filed
Jun 07, 2021
Priority
May 29, 2013 — provisional 61/828,448 +3 more
Examiner
RODRIGUEZ, RAYNA B
Art Unit
1628
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Berg LLC
OA Round
5 (Non-Final)
34%
Grant Probability
At Risk
5-6
OA Rounds
0m
Est. Remaining
53%
With Interview

Examiner Intelligence

Grants only 34% of cases
34%
Career Allowance Rate
197 granted / 588 resolved
-26.5% vs TC avg
Strong +19% interview lift
Without
With
+19.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
71 currently pending
Career history
671
Total Applications
across all art units

Statute-Specific Performance

§101
2.0%
-38.0% vs TC avg
§103
48.4%
+8.4% vs TC avg
§102
12.8%
-27.2% vs TC avg
§112
21.5%
-18.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 588 resolved cases

Office Action

§103 §DP
DETAILED ACTION This office action is in response to applicant’s filing dated April 16, 2026. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on April 16, 2026 has been entered. Status of Claims Claims 1, 2, 4, 6, 7, 9, 10, 13-15, and 22-30 are pending in the instant application. Acknowledgement is made of Applicant's remarks and amendments filed April 16, 2026. Acknowledgement is made of Applicant’s amendment of claim 1. Claims 3, 5, 8, 11, 12, 16-21, and 31-37 were previously canceled. Applicants elected without traverse breast cancer as the elected cancer species; 1,25-dihydroxyvitamin D3 as the vitamin D compound species; a formulation species comprising 1,25-dihydroxyvitamin D3 as the vitamin D compound species, and a vehicle comprising propylene glycol and anhydrous ethanol in the reply filed on May 22, 2023. The requirement is still deemed proper. Claim 25 remains withdrawn. Claims 1, 2, 4, 6, 7, 9, 10, 13-15, and 22-30 are presently under examination as they pertain to the elected species: breast cancer, calcitriol, propylene glycol and anhydrous ethanol. Priority The present application is a Continuation of US Application No. 16/424,037 filed on May 28, 2019, which is a Continuation of US Application No. 14/953,334 filed on November 28, 2015, which is a Continuation of PCT/US2014/040084 filed on May 29, 2014, which claims benefit of US Provisional Application No. 61/828,448 filed on May 29, 2013. The effective filing date of the instant application is May 29, 2013. Objections and/or Rejections and Response to Arguments Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated (Maintained Objections and/or Rejections) or newly applied (New Objections and/or Rejections, Necessitated by Amendment or New Objections and/or Rejections, NOT Necessitated by Amendment). They constitute the complete set presently being applied to the instant application. Modified Objections and/or Rejections Modifications Necessitated by Claim Amendment Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 1, 2, 4, 6, 7, 9, 10, 13-15, 22-24, and 26-30 is/are rejected under 35 U.S.C. 103 as being unpatentable over Jimenez et al (US 2011/0059917 A1, hereinafter referred to as Jimenez ‘917, cited in a previous Office Action) in view of Pitre et al (EP 1,952,808 A2, cited in a previous Office Action) and Dr. Mercola® Premium Supplements (http://products.mercola.com/vitamin-d-spray/, Internet Archive Wayback Machine date, March 3, 2011, cited in a previous Office Action) as evidenced by Sunshine Mist™ Vitamin D Spray product label obtained from the archived webpage: (https://web.archive.org/web/20110303080308/http://mercola.fileburst.com/PDF/product-labels/vitaminD-spray-label-v100.pdf, cited in a previous Office Action). Regarding claims 1, 2, 22-24, and 26-30, Jimenez ‘917 teaches a method of preventing or treating alopecia in an individual, comprising topically administering to the individual a pharmaceutical composition comprising a therapeutically effective amount of a vitamin D compound formulated to be delivered to epidermis while substantially avoiding dermis delivery (claim 1) wherein the pharmaceutical composition comprises about 40% (w/w) propylene glycol and about 60% (w/w) anhydrous absolute ethanol (200 proof, U.S.) (claim 2); wherein the vitamin D compound is 1,25-dihydroxyvitamin D3 (claim 5); wherein the alopecia is chemotherapy-induced alopecia (CIA) (claim 15); wherein alopecia has not commenced in the individual (claim 20), wherein the individual is undergoing or about to undergo chemotherapy (claim 21); wherein the pharmaceutical composition is administered to the individual prior to chemotherapy or concurrent with chemotherapy (claim 22); wherein the pharmaceutical composition does not substantially reduce the efficacy of chemotherapy (claim 24). Jimenez ‘917 teaches the composition can be formulated for topical administration in a spray [0269]. Regarding the limitation wherein the topical administering step is performed for at least one month after commencement of the chemotherapy, Jimenez ‘917 teaches in certain embodiments, the vitamin D compounds of the invention is administered to the individual over a period of about 6 weeks, 8 about weeks, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months or about a year [0169]. 1,25-Dihydroxyvitamin D3 administered 2 weeks prior to commencement of chemotherapy and concurrently with chemotherapy for about 6 weeks reads on for at least one month after commencement of the chemotherapy. Jimenez ‘917 does not explicitly teach the composition is topically administered using a metered spray unit. However, Pitre teaches a composition comprising calcitriol that is sprayable (claim 1) wherein the calcitriol is in an amount of between 0.0001 and 20% (claim 2). Pitre teaches the composition is preferably in a dosing spray bottle, for which the application area and dose characteristics are controlled and reproducible; the spray device used consists of a bottle equipped with a 25µl dosing valve [0044]. This reads on a metered spray unit. Pitre further teaches that the composition is suitable for producing a medicinal product intended for treating alopecia, in particular alopecia caused by chemotherapy or radiation [0045]. The Examiner notes that 1,25-dihydroxyvitamin D3 is equivalent to calcitriol. As such, since Jimenez ’97 teaches a method of preventing chemotherapy-induced alopecia comprising administering a therapeutically effective amount of a vitamin D compound to a patient undergoing or about to undergo chemotherapy, and since Pitre teaches a composition comprising calcitriol formulated in a spray composition for use in a metered spray bottle which is useful for treating alopecia of various origins, in particular alopecia caused by chemotherapy, it would have been prima facie obvious for a person of ordinary skill in the art before the effective filing date of the claimed invention to utilize a metered spray unit to deliver composition taught by Jimenez topically to the scalp for treating alopecia induced by chemotherapeutic agents since the prior art teaches this as a method of administration for administering calcitriol for treating alopecia induced by chemotherapeutic agents. Regarding the amounts of vitamin D of instant claims 1, 6 and 7, Jimenez ‘917 teaches in human subjects, a total dose of calcitriol (or other equivalent amount of vitamin D compounds) of about 2.5 μg, 5 μg, 10 μg, 25 μg, 50 μg, 75 μg, or 100 μg may be used. Regarding claim 10, Jimenez ‘917 teaches the concentration of the vitamin D compound in the topical formulation is about 0.1, 0.2, 0.5, 1.0, 2, 3, 5, 10, 20, 30, 50, 75, 100, 150, 200, or 400 μg/mL. MPEP 2144.05 states: In the case where the claimed ranges “overlap or lie inside ranges disclosed by the prior art” a prima facie case of obviousness exists. In re Wertheim, 541 F.2d 257, 191 USPQ 90 (CCPA 1976); In re Woodruff, 919 F.2d 1575, 16 USPQ2d 1934 (Fed. Cir. 1990). Even a slight overlap in range establishes a prima facie case of obviousness. In re Peterson, 65 USPQ2d 1379, 1382 (Fed. Cir. 2003). Regarding the limitation the pharmaceutical composition is administered in an about 1.0 mL dose (instant claim 1) or 0.25 mL (instant claim 9), Jimenez ‘917 teaches applying amounts of 5.07, 10.31, and 55.34 µg/mL administered at a dose volume of 2.1 mL [0451] ml and Pitre teaches a spray bottle with a 25µl dosing valve. Moreover, Dr. Mercola Premium Supplements Sunshine Mist™ Vitamin D Spray product label teaches serving size is 6 sprays (approximately 0.78 mL) and that the container contains approximately 32 servings. Thus, Dr. Mercola Premium Supplements teaches a metered pump designed to dispense 0.13-ml, 6 times, and that the container contains about 192 sprays. As such, since Jimenez ‘917 teaches a topical solution for inhibiting alopecia induced by chemotherapeutic agents comprising 1,25-dihydroxyvitamin D3, propylene glycol and ethyl alcohol wherein 1,25-dihydroxyvitamin D3 is administered in a concentration of 0.1, 0.2, 0.5, 1.0, 2, 3, 5, 10, 20, 30, 50, 75, 100, 150, 200, or 400 μg/mL at a dose volume of 2.1 mL, since Pitre teaches a composition comprising calcitriol formulated in a spray composition for use in a metered spray bottle equipped with a 25µl dosing valve, and since Dr. Mercola Premium Supplements teaches a metered dose spray composition comprising vitamin D wherein the serving size is 6 sprays (approximately 0.78 mL) in a container containing about 32 servings, it would have been prima facie obvious for a person of ordinary skill in the art before the effective filing date of the claimed invention to utilize the dispense dose, number of spray doses, and amount of dispenses (sprays) the container holds taught by Dr. Mercola Premium Supplements as a starting point for optimizing the spray dispenser to deliver the optimum dose of the vitamin D derivative calcitriol for supplementing the subject without overdosing. Regarding the limitation directed to administering the composition to each of the four quadrants of the scalp (instant claim 9), it would have been prima facie obvious to one of ordinary skill in the art to evenly distribute the composition across the scalp in order to evenly treat the scalp to reduce chemotherapy induced alopecia evenly throughout the scalp. Regarding claims 2 and 4, Jimenez ‘917 teaches the vitamin D compounds of the invention is topically administered to the scalp twice daily each day for two consecutive weeks prior to the commencement of chemotherapy in order to prevention or reduce the severity of any CIA that may occur upon commencement of chemotherapy [0172]. Taken together, all this would result in the practice of the method of claims 1, 2, 4, 6, 7, 9, 10, 22-24, and 26-30 with a reasonable expectation of success. Regarding claims 13-15, Jimenez ‘917 teaches the chemotherapy includes gemcitabine (claim 26) and Gemcitabine is used in the treatment of various carcinomas, including breast cancer [0357]. It would have been obvious to one of ordinary skill in the art to utilize the method of reducing chemotherapy-induced alopecia suggested by Jimenez ‘917 and Pitre in a subject having breast cancer treated with gemcitabine since the prior art teaches gemcitabine is a chemotherapeutic used to treat breast cancer, resulting in the practice of the method of claims 13-15 with a reasonable expectation of success. Response to Arguments The '917 application, Pitre, Dr. Mercola and Sunshine Mist Applicant argues: While the '917 application fully supports and enables all of the embodiments disclosed and claimed therein, the '917 application does not disclose the particular administration method required by the present claims, i.e., topically administering a pharmaceutical composition comprising therapeutically effective amount of a vitamin D compound to the scalp of the subject using a metered spray unit wherein the pharmaceutical composition comprises the vitamin D compound at a concentration of 5-20 µg/mL, and the pharmaceutical composition is administered in an about 1.0 mL dose and at a total daily dose of about 10-100 µg of the vitamin D compound for at least one month after commencement of the chemotherapy. Accordingly, the safety and efficacy of this particular administration method demonstrated by Applicant would not have been expected from the teachings of the '917 application. Pitre fails to teach or suggest any total daily dose of a Vitamin D compound, much less the particular daily dose range required. Pitre fails to provide any experimental evidence demonstrating that any treatment regimen of a Vitamin D is effective for the treatment of alopecia. Dr. Mercola and Sunshine Mist fail to cure the deficiencies of the ‘917 application and Pitre. Dr. Mercola and Sunshine Mist describe oral administration of Vitamin D. Dr. Mercola and Sunshine Mist fail to teach or suggest administering the disclosed Vitamin D spray topically to the scalp, as required by the present claims, much less the relatively high topical daily dose required by the claims as currently amended, i.e., a total daily dose of about 10-100 µg of a Vitamin D compound administered for at least one month after commencement of chemotherapy. Thus Dr. Mercola and Sunshine Mist, even when combined with Pitre and Jimenez, fail to teach or suggest that a total daily dose of about 10-100 µg of a Vitamin D compound by topical administration would result in safe and effective prevention of alopecia, as demonstrated by Applicant. Examiner's response: The above argument has been carefully considered and has not been found persuasive. Applicants are reminded that it must be remembered that the references are relied upon in combination and are not meant to be considered separately as in a vacuum. It is the combination of all of the cited and relied upon references, which make up the state of the art with regard to the claimed invention. As set forth above, Jimenez ‘917 teaches a topical solution for inhibiting alopecia induced by chemotherapeutic agents comprising 1,25-dihydroxyvitamin D3, propylene glycol and ethyl alcohol wherein 1,25-dihydroxyvitamin D3 is administered in a concentration of 0.1, 0.2, 0.5, 1.0, 2, 3, 5, 10, 20, 30, 50, 75, 100, 150, 200, or 400 μg/mL at a dose volume of 2.1 mL. As set forth above, regarding the limitation wherein the topical administering step is performed for at least one month after commencement of the chemotherapy, Jimenez ‘917 teaches in certain embodiments, the vitamin D compounds of the invention is administered to the individual over a period of about 6 weeks, 8 about weeks, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months or about a year [0169]. 1,25-Dihydroxyvitamin D3 administered 2 weeks prior to commencement of chemotherapy and concurrently with chemotherapy for about 6 weeks reads on for at least one month after commencement of the chemotherapy. As set forth above, Pitre teaches a composition comprising calcitriol formulated in a spray composition for use in a metered spray bottle equipped with a 25µl dosing valve. As set forth above, Dr. Mercola Premium Supplements teaches a metered dose spray composition comprising vitamin D wherein the serving size is 6 sprays (approximately 0.78 mL) in a container containing about 32 servings. As set forth above, it would have been prima facie obvious for a person of ordinary skill in the art before the effective filing date of the claimed invention to utilize the dispense dose, number of spray doses, and amount of dispenses (sprays) the container holds taught by Dr. Mercola Premium Supplements as a starting point for optimizing the spray dispenser to deliver the optimum dose of the vitamin D derivative calcitriol for supplementing the subject without overdosing. Maintained Objections and/or Rejections Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp. Claims 1, 2, and 27-30 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-27 of U.S. Patent No. 5,486,509 in view of Pitre et al (EP 1,952,808 A2, cited in the IDS filed January 31, 2020) and Jimenez et al (US 2011/0059917 A1, hereinafter referred to as Jimenez ‘917, cited in a previous Office Action). The instant claims are directed to a method of preventing or mitigating chemotherapy-induced alopecia in a human subject comprising administering a pharmaceutical composition comprising a therapeutically effective amount of a vitamin D compound to the scalp of the subject using a metered spray unit. The previously allowed claims are directed to a method of reducing chemotherapy-induced alopecia comprising administering an effective amount of vitamin D3 or derivative thereof (claim 1) wherein said derivative is 1,25-dihydroxyvitamin D3 (claim 2) wherein said vitamin D3 is administered topically (claim 3), wherein the composition is administered prior to the initiation of said chemotherapy (claim 9). The previously allowed claims do not specifically recite topically is administered using a metered spray unit. However, Pitre teaches a composition comprising calcitriol that is sprayable (claim 1) wherein the calcitriol is in an amount of between 0.0001 and 20% (claim 2). Pitre teaches the composition is preferably in a dosing spray bottle, for which the application area and dose characteristics are controlled and reproducible; the spray device used consists of a bottle equipped with a 25µl dosing valve [0044]. This reads on a metered spray unit. Pitre further teaches that the composition is suitable for producing a medicinal product intended for treating alopecia, in particular alopecia caused by chemotherapy or radiation [0045]. The Examiner notes that 1,25-dihydroxyvitamin D3 is equivalent to calcitriol. Jimenez ‘917 teaches a method of treating alopecia in an individual, comprising topically administering to the individual a pharmaceutical composition comprising a therapeutically effective amount of a vitamin D compound formulated to be delivered to epidermis while substantially avoiding dermis delivery (claim 1); wherein the vitamin D compound is 1,25-dihydroxyvitamin D3 (claim 5); wherein the alopecia is chemotherapy-induced alopecia (CIA) (claim 15). Moreover, Jimenez ‘917 teaches administering 5.07 and 10.31 µg/mL at a dose volume of 2.1 mL [0451]. Regarding the limitation wherein the topical administering step is performed for at least one month after commencement of the chemotherapy, Jimenez ‘917 teaches in certain embodiments, the vitamin D compounds of the invention is administered to the individual over a period of about 6 weeks, 8 about weeks, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months or about a year [0169]. 1,25-Dihydroxyvitamin D3 administered 2 weeks prior to commencement of chemotherapy and concurrently with chemotherapy for about 6 weeks reads on for at least one month after commencement of the chemotherapy. As such, it would have been prima facie obvious for a person of ordinary skill in the art before the effective filing date of the claimed invention to utilize a metered spray unit to deliver the composition recited by the previously allowed claims topically to the scalp for treating alopecia induced by chemotherapeutic agents since the prior art teaches this as a method of administration for administering calcitriol for treating alopecia induced by chemotherapeutic agents. It would have been further prima facie obvious to utilize the dose volume and dosing regimen taught by the previously allowed claims and Jimenez ‘917 as a starting point for optimizing the dosing volume for administering the vitamin D3 compound to treat alopecia induced by chemotherapeutic agents. The skilled artisan would arrive at the instant claims with a reasonable expectation of success in view of the teachings of Pitre and Jimenez ‘917. Claims 1, 2, and 27-30 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-38 of U.S. Patent No. 6,291,443 B1 in view of Pitre et al (EP 1,952,808 A2, cited in the IDS filed January 31, 2020) and Jimenez et al (US 2011/0059917 A1, hereinafter referred to as Jimenez ‘917, cited in a previous Office Action). The instant claims are directed to a method of preventing or mitigating chemotherapy-induced alopecia in a human subject comprising administering a pharmaceutical composition comprising a therapeutically effective amount of a vitamin D compound to the scalp of the subject using a metered spray unit. The previously allowed claims are directed to a method of reducing chemotherapy-induced alopecia comprising administering an effective amount of vitamin D3 or derivative thereof (claim 1) wherein said derivative is 1,25-dihydroxyvitamin D3 (claim 2) wherein said vitamin D3 is administered topically (claim 3), wherein the composition is administered prior to the initiation of said chemotherapy (claim 9). The previously allowed claims do not specifically recite topically is administered using a metered spray unit. However, Pitre teaches a composition comprising calcitriol that is sprayable (claim 1) wherein the calcitriol is in an amount of between 0.0001 and 20% (claim 2). Pitre teaches the composition is preferably in a dosing spray bottle, for which the application area and dose characteristics are controlled and reproducible; the spray device used consists of a bottle equipped with a 25µl dosing valve [0044]. This reads on a metered spray unit. Pitre further teaches that the composition is suitable for producing a medicinal product intended for treating alopecia, in particular alopecia caused by chemotherapy or radiation [0045]. The Examiner notes that 1,25-dihydroxyvitamin D3 is equivalent to calcitriol. Jimenez ‘917 teaches a method of treating alopecia in an individual, comprising topically administering to the individual a pharmaceutical composition comprising a therapeutically effective amount of a vitamin D compound formulated to be delivered to epidermis while substantially avoiding dermis delivery (claim 1); wherein the vitamin D compound is 1,25-dihydroxyvitamin D3 (claim 5); wherein the alopecia is chemotherapy-induced alopecia (CIA) (claim 15). Moreover, Jimenez ‘917 teaches administering 5.07 and 10.31 µg/mL at a dose volume of 2.1 mL [0451]. Regarding the limitation wherein the topical administering step is performed for at least one month after commencement of the chemotherapy, Jimenez ‘917 teaches in certain embodiments, the vitamin D compounds of the invention is administered to the individual over a period of about 6 weeks, 8 about weeks, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months or about a year [0169]. 1,25-Dihydroxyvitamin D3 administered 2 weeks prior to commencement of chemotherapy and concurrently with chemotherapy for about 6 weeks reads on for at least one month after commencement of the chemotherapy. As such, it would have been prima facie obvious for a person of ordinary skill in the art before the effective filing date of the claimed invention to utilize a metered spray unit to deliver the composition recited by the previously allowed claims topically to the scalp for treating alopecia induced by chemotherapeutic agents since the prior art teaches this as a method of administration for administering calcitriol for treating alopecia induced by chemotherapeutic agents. It would have been further prima facie obvious to utilize the dose volume taught by Jimenez as a starting point for optimizing the dosing volume for administering the vitamin D3 compound to treat alopecia induced by chemotherapeutic agents. The skilled artisan would arrive at the instant claims with a reasonable expectation of success in view of the teachings of Pitre and Jimenez ‘917. Claims 1, 2, 4, 6-10, 22-24, and 26-30 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-57 of U.S. Patent No. 9,901,637 B2 in view of Pitre et al (EP 1,952,808 A2, cited in the IDS filed January 31, 2020) and Jimenez et al (US 2011/0059917 A1, hereinafter referred to as Jimenez ‘917, cited in a previous Office Action). The instant claims are directed to a method of preventing or mitigating chemotherapy-induced alopecia in a human subject comprising administering a pharmaceutical composition comprising a therapeutically effective amount of a vitamin D compound to the scalp of the subject using a metered spray unit. The previously allowed claims are directed to a method of treating chemotherapy-induced alopecia comprising topically administering to the individual a pharmaceutical composition comprising a therapeutically effective amount of a vitamin D compound and a carrier, wherein the carrier consists of propylene glycol and anhydrous absolute ethanol at a % (w/w) ratio of propylene glycol to ethanol range which includes 40:60 (claim 1) (which is the same or similar to the carrier and ratio of instant claims 23 and 24); wherein the vitamin D compound is 1,25-dihydroxyvitamin D3 (claim 2); wherein alopecia has not commenced in the individual (claim 5), wherein the composition is administered to the individual prior to administration of chemotherapy or concurrent with administration of chemotherapy to the individual (claim 11); wherein the pharmaceutical composition does not substantially reduce the efficacy of the chemotherapy (claim 7). The previously allowed claims do not specifically recite that the topically administered composition is administered using a metered spray unit. However, Pitre teaches a composition comprising calcitriol that is sprayable (claim 1) wherein the calcitriol is in an amount of between 0.0001 and 20% (claim 2). Pitre teaches the composition is preferably in a dosing spray bottle, for which the application area and dose characteristics are controlled and reproducible; the spray device used consists of a bottle equipped with a 25µl dosing valve [0044]. This reads on a metered spray unit. Pitre further teaches that the composition is suitable for producing a medicinal product intended for treating alopecia, in particular alopecia caused by chemotherapy or radiation [0045]. The Examiner notes that 1,25-dihydroxyvitamin D3 is equivalent to calcitriol. Jimenez ‘917 teaches a method of treating alopecia in an individual, comprising topically administering to the individual a pharmaceutical composition comprising a therapeutically effective amount of a vitamin D compound formulated to be delivered to epidermis while substantially avoiding dermis delivery (claim 1); wherein the vitamin D compound is 1,25-dihydroxyvitamin D3 (claim 5); wherein the alopecia is chemotherapy-induced alopecia (CIA) (claim 15). Moreover, Jimenez ‘917 teaches administering 5.07 and 10.31 µg/mL at a dose volume of 2.1 mL [0451]. Regarding the limitation wherein the topical administering step is performed for at least one month after commencement of the chemotherapy, Jimenez ‘917 teaches in certain embodiments, the vitamin D compounds of the invention is administered to the individual over a period of about 6 weeks, 8 about weeks, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months or about a year [0169]. 1,25-Dihydroxyvitamin D3 administered 2 weeks prior to commencement of chemotherapy and concurrently with chemotherapy for about 6 weeks reads on for at least one month after commencement of the chemotherapy. As such, since the instant claims are directed to a method of preventing chemotherapy-induced alopecia comprising administering a therapeutically effective amount of a vitamin D compound to a patient undergoing or about to undergo chemotherapy, and since Pitre teaches a composition comprising calcitriol formulated in a spray composition for use in a metered spray bottle which is useful for treating alopecia of various origins, in particular alopecia caused by chemotherapy, it would have been prima facie obvious for a person of ordinary skill in the art before the effective filing date of the claimed invention to utilize a metered spray unit to deliver composition taught by Jimenez topically to the scalp for treating alopecia induced by chemotherapeutic agents since the prior art teaches this as a method of administration for administering calcitriol for treating alopecia induced by chemotherapeutic agents. It would have been further prima facie obvious to utilize the dose volume taught by Jimenez as a starting point for optimizing the dosing volume for administering the vitamin D3 compound to treat alopecia induced by chemotherapeutic agents. The skilled artisan would arrive at the instant claims with a reasonable expectation of success in view of the teachings of Pitre and Jimenez ‘917. Regarding the amounts of vitamin D of instant claims 6-8 and 10, the previously allowed claims are directed to wherein the pharmaceutical composition comprises 3-100 μg/mL of 1,25-dihydroxyvitamin D3; and wherein the pharmaceutical composition comprises about 5, 10 or 20 μg/mL of 1,25-dihydroxyvitamin D3. It would have prima facie obvious to utilize the amounts of the previously granted claims to arrive at the doses and amounts of the sprayable composition of the instant claims. Similarly, it would have been well with the skill of the skilled artisan to optimize the treatment regimen recited in the previously granted claims to arrive at the treatment regimen of instant claims 3, 4, 9, 11 and 12, Jimenez ‘917 teaches the vitamin D compounds of the invention is topically administered to the scalp twice daily each day for two consecutive weeks prior to the commencement of chemotherapy in order to prevention or reduce the severity of any CIA that may occur upon commencement of chemotherapy [0172]. Two weeks prior to commencement of chemotherapy reads on the limitation “wherein step (2) is performed for a sufficient time prior to the commencement of chemotherapy such that the catagen stage of hair follicles is induced in the treated area of the subject” as evidenced by instant claim 4. Regarding previously allowed claims 49-58 which are directed to a pharmaceutical composition comprising vitamin D compounds, the composition of the previously allowed claims would anticipate the instantly claimed composition. In Sun Pharmaceutical Industries Ltd. v. Eli Lilly and Co., 95 USPQ2d 1797 (Fed. Cir. 2010), the Court determined that Claims of a later patent were held invalid for obviousness-type double patenting when the earlier patent claimed a compound and disclosed its utility in specification, and later patent claimed a method of using compound for use described in specification of earlier patent. Claims 1, 2, 4, 6-10, 22-24, and 26-30 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-20 of U.S. Patent No. 11,305,016 B2. The previously allowed claims are directed to a pharmaceutical composition comprising a vitamin D compound, propylene glycol and ethanol which would anticipate the instantly claimed composition. The specification of the previously allowed claims discloses the composition can be formulated in a spray formulation, and the compositions are useful for preventing or treating alopecia in an individual by topically administering the composition (col 1, lines 56-61) wherein the alopecia is chemotherapy induced alopecia (page 1, lines 50-54) and dose concentrations were 5.07 and 10.31 µg/mL at a dose volume of 2.1 mL (col 68, lines 18-19). In Sun Pharmaceutical Industries Ltd. v. Eli Lilly and Co., 95 USPQ2d 1797 (Fed. Cir. 2010), the Court determined that Claims of a later patent were held invalid for obviousness-type double patenting when the earlier patent claimed a compound and disclosed its utility in specification, and later patent claimed a method of using compound for use described in specification of earlier patent. Claims 1, 2, 4, 6-10, 22-24, and 26-30 provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 2, 5, 9-11, 13-17, 19, 28-31, 33, 38, 40, and 44 of copending Application No. 17/981,038 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because: The instant claims are directed to a method of preventing or mitigating chemotherapy-induced alopecia in a human subject comprising administering a pharmaceutical composition comprising a therapeutically effective amount of a vitamin D compound to the scalp of the subject using a metered spray unit. The copending claims are directed to a method of preventing or mitigating chemotherapy-induced alopecia in a human subject comprising the steps of:(1) selecting a human subject having a cancer and who is scheduled to receive, or is receiving, a chemotherapy; and (2) topically administering a pharmaceutical composition comprising a vitamin D compound in a total daily dose of 105 µg to 180 µg of the vitamin D compound to the scalp of the subject, wherein step (2) is performed prior to and/or concurrently with the chemotherapy, thereby preventing or mitigating chemotherapy-induced alopecia in the subject (claim 1), wherein the pharmaceutical composition is administered in an about 1.0 mL dose (claim 9); wherein about 0.25 mL is administered to each of the four quadrants of the scalp (claim 10) wherein the pharmaceutical composition is administered using a metered spray unit (claim 13). The copending claims differ from the instant claims in the amount of vitamin D administered. However, it would be obvious to utilize the amounts of vitamin D recited in the copending claims as a starting point for optimizing the amount of vitamin D administered to arrive at the method of the instant claims because dosage and treatment regimen are result-effective variables, i.e. a variable that achieves a recognized result. Therefore, the determination of the optimum or workable dosages would have been well within the practice of routine experimentation by the skilled artisan. Furthermore, absent any evidence demonstrating a patentable difference between the compositions and the criticality of the claimed dosage range, the determination of the optimum or workable dosing regimen given the guidance of the prior art would have been generally prima facie obvious to the skilled artisan. Please see MPEP 2144.05 [R-2](II)(A) and In re Aller, 220 F. 2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). ("[W]here the general conditions of claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation."). This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Response to Arguments Applicant argues: Claims 1, 2, and 27-30 were rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-27 of U.S. Patent No. 5,486,509 (Jimenez) in view of Pitre. Applicant respectfully traverses the rejection. The present claims as currently amended are not obvious over claims 1-27 of Jimenez in view of Pitre for at least the reasons provided above under the obviousness rejection. Examiner's response: The above argument has been carefully considered and has not been found persuasive. Applicant has not independently argued the merits of this rejection. Arguments regarding Pitre and ‘917 and the obviousness rejection have been addressed above. Therefore, the rejection is maintained for the reasons set forth on the record and for those set forth in the response to the arguments above. Applicant argues: Claims 1, 2, and 27-30 were rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-38 of U.S. Patent No. 6,291,443 B1 in view of Pitre. Applicant respectfully requests that the rejection be held in abeyance until allowable subject matter is indicated in the present application. Examiner's response: The above argument has been carefully considered and has not been found persuasive. Applicant’s request for maintaining the rejection on the grounds of non-statutory obviousness-type double patenting over US Patent No. 6,291,443 B1 is noncompliant with the regulations under 37 C.F.R. 1.111. The instant rejection is not a provisional rejection as the claims of US Patent 6,291,443 B1 have been issued. In the interest of compact prosecution, the examiner has examined the instant application. However, in order for the response to the instant Office Action to be fully responsive and in compliance with the regulations under 37 C.F.R. 1.111, the Applicant should either file a terminal disclosure or traverse the rejection based on US Patent No. 6,291,443 B1. Because applicant did not distinctly and specifically point out the supposed errors in the instant non-statutory obviousness-type double patent rejection in view of US Patent No. 6,291,443 B1 and no Terminal Disclaimer has been filed, the rejection is maintained. Applicant argues: Claims 1, 2, 4, 6-10, 22-24, and 26-30 were rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-57 of U.S. Patent No. 9,901,637 B2 in view of Pitre. The '637 patent issued from the '917 application discussed above under the obviousness rejection. Thus, the claims as currently amended are not obvious over claims 1-57 of the '637 patent for at least the reasons provided above regarding the '917 application. Accordingly, reconsideration and withdrawal of the rejection are respectfully requested. Examiner's response: The above argument has been carefully considered and has not been found persuasive. Applicant has not independently argued the merits of this rejection. Arguments regarding Pitre and ‘917 application and the obviousness rejection have been addressed above. Therefore, the rejection is maintained for the reasons set forth on the record and for those set forth in the response to the arguments above. Applicant argues: Claims 1, 2, 4, 6-10, 22-24, and 26-30 were rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-20 of U.S. Patent No. 11,305,016 B2. Applicant respectfully traverses the rejection. The '016 patent issued from a continuation application claiming priority to the '917 application discussed above under the obviousness rejection. Thus, the claims as currently amended are not obvious over claims 1-20 of the '016 patent for at least the reasons provided above regarding the '917 application. Accordingly, reconsideration and withdrawal of the rejection are respectfully requested. Examiner's response: The above argument has been carefully considered and has not been found persuasive. Applicant has not independently argued the merits of this rejection. Arguments regarding Pitre and 928 application and the obviousness rejection have been addressed above. Therefore, the rejection is maintained for the reasons set forth on the record and for those set forth in the response to the arguments above. Applicant argues: Claims 1, 2, 4, 6-10, 22-24, and 26-30 were provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 2, 5, 9-11, 13-17, 19, 28-31, 33, 38, 40, and 44 of copending Application No. 17/981,038. Applicant respectfully requests that the rejection be held in abeyance until allowable subject matter is indicated in the present application. Examiner's response: With regard to the double patenting rejection, applicant's request for this rejection to be held in abeyance until all other rejections are overcome has been acknowledged. The double patenting rejection is maintained and held in abeyance. Conclusion Claims 1, 2, 4, 6, 7, 9, 10, 13-15, 22-24, and 26-30 are rejected. No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to RAYNA B RODRIGUEZ whose telephone number is (571)272-7088. The examiner can normally be reached 8am-5:00pm, Monday - Thursday. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amy L Clark can be reached at 571-272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Rayna Rodriguez/ Primary Examiner, Art Unit 1628
Read full office action

Prosecution Timeline

Show 4 earlier events
Oct 10, 2024
Request for Continued Examination
Oct 15, 2024
Response after Non-Final Action
Mar 20, 2025
Non-Final Rejection mailed — §103, §DP
Sep 22, 2025
Response Filed
Oct 16, 2025
Final Rejection mailed — §103, §DP
Apr 16, 2026
Request for Continued Examination
Apr 22, 2026
Response after Non-Final Action
Jul 28, 2026
Non-Final Rejection mailed — §103, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778928
ANTI-INFLAMMATORY COMPOSITION COMPRISING BENZOFURAN-BASED N-ACYLHYDRAZONE DERIVATIVES
3y 9m to grant Granted Nov 03, 2026
Patent 12780867
STEROL BASED IONIZABLE LIPIDS AND LIPID NANOPARTICLES COMPRISING THE SAME
2y 1m to grant Granted Nov 03, 2026
Patent 12751951
CDK INHIBITORS
1y 4m to grant Granted Oct 06, 2026
Patent 12740983
CDK INHIBITORS
1y 4m to grant Granted Sep 22, 2026
Patent 12740984
CDK INHIBITORS
1y 4m to grant Granted Sep 22, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
34%
Grant Probability
53%
With Interview (+19.2%)
3y 5m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 588 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month